foxo4-dri peptide senolytic mouse study 2023 Frontiers Molecular modelling of the FOXO4-TP53
Description
H.ZhugeX
These preclinical findings further implicate glucagon activation as the distinguishing factor between incretin receptor mono-, dual-, and triagonists, and they point to unimolecular polypharmacology as an efficient way to target several mechanisms causing obesity
suggesting a role of the gut microbiota in T1D-induce bone loss
For intramuscular injections, 22-25 gauge is preferred, while for subcutaneous injections, 25-27 gauge is suitable
Cartilage 12 (4), 512525
Nature 1948;161:638
